concord wellness kacip fatimah plus capsules
concord trading sdn. bhd. - croton caudatum; labisia pumila -
concor 5 mg
merck serono ltd - bisoprolol fumarate - tablets - bisoprolol fumarate 5 mg - bisoprolol - - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.- hypertension- coronary heart disease (angina pectoris)
concor 1.25 mg
merck serono ltd - bisoprolol fumarate - film coated tablets - bisoprolol fumarate 1.25 mg - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.
concor 2.5 mg
merck serono ltd - bisoprolol fumarate - film coated tablets - bisoprolol fumarate 2.5 mg - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.
concor 10mg film coated tablet
merck sdn. bhd. - bisoprolol fumarate -
concor 2.5mg film coated tablet
merck sdn. bhd. - bisoprolol fumarate -
concord birth trolley - infant resuscitation table
vicki partridge pty ltd - 36685 - infant resuscitation table - birth trolley, with mattress, which enables caregivers to deliver medical care to neonates immediately after birth.
concord 300sc
adria new zealand ltd - cymoxanil - cymoxanil 300 g/litre - fungicide
zonegran- zonisamide capsule
concordia pharmaceuticals inc. - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 25 mg - zonegran is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonegran is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonegran has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.
concor 5mg film coated tablet
merck sdn. bhd. - bisoprolol fumarate -